Key Takeaways
- • Artificial intelligence and policy uncertainty are top concerns for healthcare dealmakers, according to attendees at McDermott Will & Schulte's annual New York private-equity healthcare conference.
- • Buyers are increasingly demanding proven market resilience and insulation from government changes amid an uneven market recovery.
- • McDermott Chairman Ira Coleman told conference attendees that the policy environment "may be changing in a pretty profound way" and that investors and operators must plan around it.
Summary
Artificial intelligence and policy uncertainty are dominating the agenda for healthcare dealmakers, according to attendees at law firm McDermott Will & Schulte's recent annual New York private-equity healthcare conference, as reported by The Wall Street Journal.
Against a backdrop of an uneven market recovery, buyers are increasingly seeking assets with proven market resilience and insulation from government-driven changes. That shift reflects a broader reassessment of the sector's traditional private-equity playbook, which has relied heavily on reimbursement-dependent business models exposed to regulatory decisions.
McDermott Chairman Ira Coleman addressed the room directly, saying, "The policy ground beneath us may be changing in a pretty profound way, and it's a variable every investor and operator in this room really needs to plan around or at least take into consideration." His remarks underscore the degree to which regulatory risk is now being priced into healthcare investment decisions.
The Journal's coverage points to AI and regulation as the two forces most likely to shape healthcare deal activity in the near term, with sponsors and operators needing to assess both technological disruption and policy exposure when underwriting new healthcare transactions.
Against a backdrop of an uneven market recovery, buyers are increasingly seeking assets with proven market resilience and insulation from government-driven changes. That shift reflects a broader reassessment of the sector's traditional private-equity playbook, which has relied heavily on reimbursement-dependent business models exposed to regulatory decisions.
McDermott Chairman Ira Coleman addressed the room directly, saying, "The policy ground beneath us may be changing in a pretty profound way, and it's a variable every investor and operator in this room really needs to plan around or at least take into consideration." His remarks underscore the degree to which regulatory risk is now being priced into healthcare investment decisions.
The Journal's coverage points to AI and regulation as the two forces most likely to shape healthcare deal activity in the near term, with sponsors and operators needing to assess both technological disruption and policy exposure when underwriting new healthcare transactions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.